Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This study assesses the potential of using a TGFβ receptor inhibitor for the treatment of
anemic patients with myeloproliferetive neoplasms. TGFβ signaling is known to be abnormally
high in patients with myeloproliferative neoplasms and it is thought that abnormal TGFβ
signals cause many of the problems with blood cell formation in these diseases. The study
design allows all patients to receive the study drug, vactosertib. The dose of vactosertib is
individualized within a pre-set range based upon its effectiveness and tolerability. A total
of up to 37 patients will be treated.